Delcath Systems, Inc. (NASDAQ: DCTH) is a Healthcare company (Medical - Devices) with a market capitalization of $674M. The Maz Rating grades it against the other companies in its sector.
Delcath Systems, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $19.37, Delcath Systems, Inc. trades at 109.0x trailing earnings, 6.1x sales and 5.2x book value, with an EV/EBITDA of 66.9. Over the last twelve months it generated about $110M of revenue and $6M of net income. It runs a gross margin of 87.6%, an operating margin of 5.2% and a net margin of 6.1%. It shows return on equity of 5.6%, return on invested capital of 3.1% and a free cash flow yield of 3.0%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 10.87. Over the past 52 weeks the share price ranged from $8.12 to $22.51, with a beta of 0.60.
Delcath Systems, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 8 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Delcath Systems, Inc. (DCTH) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 18.0% / 30% · Interest income / Revenue 2.43% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 18.0% / 33% · Receivables / Mkt Cap (36m) 3.48% / 49% · Interest income / Revenue 2.43% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 18.0% / 33.33% · Receivables / Mkt Cap (24m) 3.48% / 33.33% · Interest income / Revenue 2.43% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.15% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 71.2% / 33.33% · Receivables / Avg Assets (4Q) 12.0% / 33.33% · Interest income / Revenue 2.43% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 70.0% / 33.33% · (Cash+Recv) / Total Assets 83.5% / 33.33% · Interest income / Revenue 2.43% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Delcath Systems, Inc. (DCTH) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Delcath Systems, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.43% of each dividend: Delcath Systems, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.